Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MIRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMIRA expands Ketamir-2 license from North America to global patent territories
Filed May 27, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
high
MIRA expanded exclusive rights to develop Ketamir-2 from US, Canada, and Mexico to all countries where patent rights exist, significantly broadening potential market opportunity for the Phase 2a drug candidate.
Item 1.01 verify on EDGAR → -
high
Licensed patent portfolio now covers ten major markets including US, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea, strengthening competitive position and IP protection globally.
Item 1.01 verify on EDGAR → -
medium
Amendment did not change core economic terms including royalty obligations and financial consideration, meaning MIRA secured expanded global rights without renegotiating payment terms or disclosed additional costs.
Item 1.01 verify on EDGAR →
Summary
MIRA Pharmaceuticals amended its exclusive license agreement with MIRALOGX on May 21, 2026, dramatically expanding its territorial rights for Ketamir-2, a drug candidate currently advancing toward Phase 2a development. The company transformed a North America-only license into global coverage spanning all countries where patent rights exist, with specific patent filings now secured across ten major pharmaceutical markets including the US, Europe, China, and Japan. For retail investors, this represents a significant de-risking and value expansion event.
MIRA now controls worldwide commercialization rights for Ketamir-2 without having to renegotiate royalty rates or pay disclosed additional fees—suggesting management secured favorable terms. The broader patent coverage reduces the risk of geographic limitations constraining future partnerships or market entry. Watch for updates on the Phase 2a trial timeline and any partnership discussions, as the expanded global rights make MIRA a more attractive collaboration partner for larger pharmaceutical companies seeking worldwide development and commercialization opportunities.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
MIRA amended its exclusive license agreement with MIRALOGX on May 21, 2026.
Added in current filing · verify on EDGAR →
Amendment No. 1 to Exclusive License Agreement, by and between the Company and MIRALOGX, dated as of May 21, 2026.
MIRA Pharmaceuticals entered into Amendment No. 1 to its Exclusive License Agreement with MIRALOGX on May 21, 2026. The 8-K does not disclose the specific terms or changes made in this amendment, only that it was executed and announced via press release.
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Pursuant to the Amendment, the parties expanded the Company’s exclusive licensed territory relating to Ketamir-2 from the United States, Canada, and Mexico to all countries in which patent rights exist.
The company significantly expanded its exclusive rights to develop and commercialize Ketamir-2 from three North American countries to global coverage wherever patents exist. This broadens the potential market opportunity for the drug candidate as it advances toward Phase 2a development.
Added in current filing · verify on EDGAR →
The Amendment also expands the licensed patent portfolio to include international patent filings and applications across multiple jurisdictions, including the United States, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea.
The licensed patent portfolio now includes filings across ten major global markets, providing broader intellectual property protection. This expansion strengthens the company's competitive position and potential commercialization rights in key pharmaceutical markets worldwide.
Added in current filing · verify on EDGAR →
The Amendment did not materially modify the previously disclosed core economic terms of the original License Agreement, including royalty obligations and other financial consideration.
Despite the significant expansion in territory and patent coverage, the company did not have to renegotiate royalty rates or other financial terms. This suggests favorable economics for the expanded rights and no additional upfront or milestone payment obligations were disclosed.
Event · Item 7.01 — Regulation FD Disclosure
Company issued press release announcing execution of an amendment, furnished under Regulation FD.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On May 27, 2026, the Company issued a press release announcing the execution of the Amendment.
The company disclosed that it executed an amendment and issued a press release about it on May 27, 2026.This is a Regulation FD disclosure, meaning the information is being furnished to ensure fair disclosure to all investors simultaneously.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify